切除修复交又互补基因1在小细胞肺癌中的表达及意义  

Excision Repair Cross Complementing-1 Gene Expression in Small Cell Lung Cancer and Chemo-sensitivity to Cisplatin/Etoposide Regimen

作　　者：李福根[1] 杨帆[2] 孙美侬[3] 姜冠潮[2] 

机构地区：[1]北京胸科医院胸外科 [2]北京大学人民医院 [3]河南安阳地区医院

出　　处：《结核病与胸部肿瘤》2009年第3期181-183,共3页Tuberculosis and Thoracic Tumor

摘　　要：目的观察小细胞肺癌标本中切除修复交叉互补基因1（ERCC1）表达的特点及其对顺铂联合化疗效果的影响。方法对60例初治小细胞肺癌患者的气管镜活检标本，用免疫组织化学方法检测ERCCI蛋白，同时分析ERCC1蛋白水平与顺铂／依托泊苷化疗疗效关系、患者中位生存期的关系。结果ERCC1在小细胞肺癌标本中表达率为23．3％，与病程和患者年龄无明显相关。ERCC1表达阳性患者顺铂／依托泊苷一线化疗有效率为42．9％，显著低于ERCCI（-）患者的73．1％。结论ERCC1在部分小细胞肺癌标本存在表达，ERCC1阳性的小细胞肺癌对顺铂的化疗敏感性降低。Objective To evaluate the expression pattern of excision repair cross comlementing-1 （ERCCl）gene and its relation with ciaplatin- based chemotherapy.Methods Sixty small-cell lung cancer samples were studied for ERCCI expression by immunohistochemistry.The association of ERCC1 gene expression to response of cisplatin/etoposide chemotherapy and patients＇ survival was analyzed.Results ERCC1 expression detected by immunohistochemistry was 23.3 % in small-cell lung cancer samples and not related to stage or age of patients.Response rate in ERCC1 positive patients to cisplatin/etoposide chemotherapy was 42.3 %, which was significantly lower than that in ERCC1 （-） patients of 73.1%. Statistical significance was not reached for ERCC1 expression and median survival analysis.Conclusion ERCC1 expression in small- cell lung cancer samples could serve as predictive marker for first-line cisplatin/etoposide chemotherapy.

关 键 词：小细胞肺癌 基因表达 顺铂 

分 类 号：R734.2[医药卫生—肿瘤] R394[医药卫生—临床医学]